Login / Signup

Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.

Clara MazagatosJacobo MendiorozMercedes Belén RumayorVirtudes Gallardo GarcíaVirginia Álvarez RíoAna Delia Cebollada GraciaNoa Batalla RebolloMaría Isabel Barranco BoadaOlaia Pérez-MartínezAna Sofía Lameiras AzevedoNieves López González-CoviellaDaniel CastrillejoAna Fernández IbáñezJaume Giménez DuranCristina Ramírez CórcolesVioleta Ramos MarínLarrauri AmparoSusana Mongenull null
Published in: Influenza and other respiratory viruses (2024)
We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.
Keyphrases
  • respiratory syncytial virus
  • emergency department
  • young adults
  • risk factors
  • healthcare
  • adverse drug